APPENDIX D TO APPENDIX C 
The MUA should bear the NIH grant/contract number and must be signed 
both by the appropriate institutional official and the orincioal 
investigator. The original and one copy are to be submitted to the 
NIH Office of Recombinant CWA Activities no later than November 15. 
In those cases in which the NIH awarding component or the Office of 
Recombinant DNA Activities finds that a project requires a higher 
level of containment than proposed by the principal investigator and 
the institution, the Office of Recombinant DtQA Activities v^ill work 
with the principal investigator and the institution to develop a 
revised MUA. 
Prio r App ro val Req uirem ent for Chang es In Aw arded Projects 
Effective immediately, prior approval by a scientist administrator 
of the NIH awarding component is required before experiments involving 
recombinant DNA molecules may be conducted in any ongoing project 
vs^ich has not been reviewed and approved for the use of recon±)inant 
DNA technology. 
Effectively immediately, prior approval by a scientist administrator 
of the NIH awarding component is required for any significant al- 
teration of an approved protocol, such as when a principal investigator 
proposes to clone DNA segments other than those originally reviewed 
and approved. 
In the cases cited above the institution and principal investigator 
must first apply to the relevant scientist administrator of the NIH 
awarding component for permission before proceeding. The request 
to conduct such experiments must be accompanied by a new or revised 
MUA as described under IV. The latter will be reviewed by the NIH 
awarding component and the Office of Recombinant DNA Activities. 
VI . New, Continuation, an d Com peting Renewal A pplications 
Procedures for the submission of new, continuation and competing 
renewal applications proposing to utilize recombinant DNA technology 
will be described in a forthconing N IH Guide for Grants and Contracts 
regarding the control of recombinant DNA moiecules. The latter will 
supersede this interim policy statement. NIH v;ill require all the 
information and documentation described under IV at the time of 
submission of an application to NIH. 
Appendix C — 23 
